as of 11-06-2026 3:51pm EST
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 3.2B | IPO Year: | 2013 |
| Target Price: | $59.73 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.04 | EPS Growth: | 164.52 |
| 52 Week Low/High: | $29.45 - $60.91 | Next Earning Date: | 11-04-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 14.82% | Revenue Growth (next year): | 11.16% |
| P/E Ratio: | 50.50 | Index: | |
| Free Cash Flow: | 126.6M | FCF Growth: | +64.90% |
Director
Avg Cost/Share
$50.00
Shares
14,850
Total Value
$742,572.77
Owned After
10,247
SEC Form 4
Director
Avg Cost/Share
$50.00
Shares
7,500
Total Value
$375,000.00
Owned After
27,471
SEC Form 4
Director
Avg Cost/Share
$43.70
Shares
1,864
Total Value
$81,456.80
Owned After
40,854
SEC Form 4
Director
Avg Cost/Share
$47.00
Shares
7,500
Total Value
$352,500.00
Owned After
27,471
SEC Form 4
Global Chief Commercial Off
Avg Cost/Share
$40.00
Shares
4,015
Total Value
$160,600.00
Owned After
124,329
SEC Form 4
Director
Avg Cost/Share
$40.95
Shares
5,000
Total Value
$204,747.00
Owned After
27,471
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$43.26
Shares
3,652
Total Value
$157,394.16
Owned After
167,200
EVP, General Counsel
Avg Cost/Share
$43.23
Shares
3,254
Total Value
$140,212.09
Owned After
131,160
Chief Scientific & Med Officer
Avg Cost/Share
$43.28
Shares
13,110
Total Value
$564,409.96
Owned After
133,048
Director
Avg Cost/Share
$42.97
Shares
1,864
Total Value
$80,096.08
Owned After
40,854
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| EASTHAM KARIN | VCYT | Director | Oct 27, 2026 | Sell | $50.00 | 14,850 | $742,572.77 | 10,247 | |
| Holstein Jens | VCYT | Director | Oct 27, 2026 | Sell | $50.00 | 7,500 | $375,000.00 | 27,471 | |
| Bhanji Muna | VCYT | Director | Oct 19, 2026 | Sell | $43.70 | 1,864 | $81,456.80 | 40,854 | |
| Holstein Jens | VCYT | Director | Sep 24, 2026 | Sell | $47.00 | 7,500 | $352,500.00 | 27,471 | |
| Leite John | VCYT | Global Chief Commercial Off | Sep 21, 2026 | Sell | $40.00 | 4,015 | $160,600.00 | 124,329 | |
| Holstein Jens | VCYT | Director | Sep 14, 2026 | Sell | $40.95 | 5,000 | $204,747.00 | 27,471 | |
| Chambers Rebecca | VCYT | Chief Financial Officer | Sep 4, 2026 | Sell | $43.26 | 3,652 | $157,394.16 | 167,200 | |
| McGuire Annie | VCYT | EVP, General Counsel | Sep 4, 2026 | Sell | $43.23 | 3,254 | $140,212.09 | 131,160 | |
| Febbo Phillip G. | VCYT | Chief Scientific & Med Officer | Sep 4, 2026 | Sell | $43.28 | 13,110 | $564,409.96 | 133,048 | |
| Bhanji Muna | VCYT | Director | Sep 1, 2026 | Sell | $42.97 | 1,864 | $80,096.08 | 40,854 |
SEC 8-K filings with transcript text
Nov 4, 2026 · 100% conf.
1D
-5.96%
$47.29
5D
-8.42%
$46.05
20D
-12.39%
$44.06
vcyt-20261104
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 4, 2026
(Exact name of registrant as specified in its charter)
Delaware
001-36156
20-5455398
(State or other jurisdiction of
incorporation)
Commission File Number
(IRS Employer Identification
No.)
6000 Shoreline Court, Suite 300, South San Francisco, California
94080
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: (650) 243-6300
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On November 4, 2026, Veracyte, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this report.
The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 8.01. Other Events.
On November 4, 2026, the Company announced the commencement of a share repurchase program previously authorized by the Board of Directors of the Company, pursuant to which the Company may repurchase up to $100.0 million of its outstanding common stock during the one-year period beginning on the date of the public announcement of the program (the “Repurchase Program”). Repurchases under the Repurchase Program may be made from time to time in open-market transactions, including in accordance with Rule 10b-18 under the Exchange Act or pursuant to trading plans adopted in accordance with Rule 10b5-1 under the Exchange Act, privately negotiated transactions, accelerated share repurchase transactions or other transactions, in each case in accordance with applicable laws and regulations.
The timing, amount and terms of any repurchases will depend on a variety of factors, including market conditions, the trading price of the Company’s common stock, the Company’s financial position and results of operations, capital requirements, general business conditions, alternative investment opportunities and other factors the Company deems relevant. The Repurchase Program does not obligate the Company to repurchase any specific number of shares and may be modified, suspended or discontinued at any time without prior notice at the Company’s discretion.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.Description
99.1 Press release issued by Veracyte, Inc. dated November 4, 2026.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: November 4, 2026
By: /s/ Rebecca Chambers
Name: Rebecca Chambers
Title: Chief Financial Officer
Principal Financial Officer
Jul 30, 2026 · 100% conf.
1D
+10.33%
$66.14
Act: -22.52%
5D
+14.15%
$68.43
20D
+19.43%
$71.60
vcyt-20260730
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 30, 2026
(Exact name of registrant as specified in its charter)
Delaware
001-36156
20-5455398
(State or other jurisdiction of
incorporation)
Commission File Number
(IRS Employer Identification
No.)
6000 Shoreline Court, Suite 300, South San Francisco, California
94080
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: (650) 243-6300
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On July 30, 2026, Veracyte, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this report.
The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.Description
99.1 Press release issued by Veracyte, Inc. dated July 30, 2026.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: July 30, 2026
By: /s/ Rebecca Chambers
Name: Rebecca Chambers
Title: Chief Financial Officer
Principal Financial Officer
May 5, 2026 · 100% conf.
1D
+8.73%
$35.85
Act: +24.93%
5D
+13.53%
$37.43
Act: +19.99%
20D
+16.33%
$38.35
Act: +47.68%
SEC.gov | Request Rate Threshold Exceeded
U.S. Securities and Exchange Commission
You’ve Exceeded the SEC’s Traffic Limit
Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.
Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.
The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.
For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.
For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.
Reference ID: 0.c706d217.1784986021.44c4f250
More Information
Internet Security Policy
By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.
Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.
Note: We do not offer technical support for developing or debugging scripted downloading processes.
See how VCYT stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "VCYT Veracyte Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.